title: CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.
authors: 1] Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA [2] Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
authors: M P
authors: MP
authors: Goetz
authors: Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
authors: J N
authors: JN
authors: Ingle
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism* / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005838:Genotype; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D013629:Tamoxifen / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6